David Reese
Amministratore Delegato presso CHEMOCENTRYX, INC.
Patrimonio netto: 17 M $ in data 30/04/2024
Profilo
Fondatore di Translational Oncology Research International, Inc., David M. Reese è vicepresidente esecutivo di ricerca e sviluppo presso Amgen, Inc. Il Dr. Reese ha precedentemente ricoperto la posizione di Direttore-Ricerca clinica presso il Breast Cancer International Research Group Ltd. e di Direttore-Ricerca clinica presso la Translational Research In Oncology. Ha conseguito una laurea presso l'Harvard College e una laurea presso l'Università di Cincinnati College of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AMGEN INC.
0.01% | 07/05/2024 | 61 889 ( 0.01% ) | 17 M $ | 30/04/2024 |
Posizioni attive di David Reese
| Società | Posizione | Inizio |
|---|---|---|
| AMGEN INC. | Direttore Tecnico/Scientifico/R&S | 26/07/2018 |
| FIVE PRIME THERAPEUTICS, INC. | Amministratore Delegato | - |
| CHEMOCENTRYX, INC. | Amministratore Delegato | - |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Amministratore Delegato | - |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Presidente | - |
CEO Roundtable on Cancer, Inc.
 CEO Roundtable on Cancer, Inc. Miscellaneous Commercial ServicesCommercial Services CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC. | Direttore/Membro del Consiglio | - |
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Amministratore Delegato | - |
Alantos Pharmaceuticals Holding, Inc.
 Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Presidente | - |
Research!America
 Research!America Miscellaneous Commercial ServicesCommercial Services Research!America is a lobbying firm. The non-profit company is based in Alexandria, VA. The CEO of the company is Mary Woolley. | Direttore/Membro del Consiglio | 22/04/2023 |
Precedenti posizioni note di David Reese
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di David Reese
| Harvard College | Undergraduate Degree |
| The University of Cincinnati College of Medicine | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Aziende private | 11 |
|---|---|
| Translational Research In Oncology | |
| Breast Cancer International Research Group Ltd. | |
| Translational Oncology Research International, Inc. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
CEO Roundtable on Cancer, Inc.
CEO Roundtable on Cancer, Inc. Miscellaneous Commercial ServicesCommercial Services CEO Roundtable on Cancer, Inc. promotes activities to reduce cancer risk, enable early detection, facilitate better access to treatment and hasten the discovery. Its programs include CEO cancer gold standard, life sciences consortium and project data sphere. The company was founded by George H. W. Bush in 2001 and is headquartered in Durham, NC. | Commercial Services |
KAI Pharmaceuticals, Inc.
KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Alantos Pharmaceuticals Holding, Inc.
Alantos Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Research!America
Research!America Miscellaneous Commercial ServicesCommercial Services Research!America is a lobbying firm. The non-profit company is based in Alexandria, VA. The CEO of the company is Mary Woolley. | Commercial Services |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
- Borsa valori
- Insiders
- David Reese
